Synonyms: ACD-855 | ACD855 | Marquis® (vet use only) | toltrazuril | toltrazuril sulfone
Compound class:
Synthetic organic
Comment: Ponazuril is a safe and well tolerated anti-protozoal drug used in horses [2]. Repurposing efforts have identified it as a tropomyosin related kinase (Trk) receptor positive allosteric modulator (PAM), on the hypothesis that increasing NGF/BDNF signalling is predicted to improve neuronal cell functions and survival to boost cognitive capacity in neurological/neurodegenerative diseases. This work by AlzeCure Pharma led to ponazuril's re-naming with their in-house research code ACD855 [1]. ACD855 enhances signalling of the neurotrophins NGF and BDNF via TrkA and TrkB (repectively). It is structurally related to their TrkA-selective lead compound ACD856 that is in clinical development as a novel Alzheimer's disease therapeutic [5].
ACD856's chemical structure has not been disclosed (Oct 2022), but a number of derivatives with the same 1,3,5-triazine scaffold have been claimed as Trk PAMs in AlzeCure patents WO2020002950A1 [3] and WO2018115891A1 [4]. |
|
Bioactivity Comments |
ACD855 enhances TrkA and TrkB signalling (NGF- or BDNF-mediated respectively), but does not alter signalling via TrkC, IGF1R or FGFR1 [1]. In vitro ACD855 enhances NGF/TrkA activity to ~140% compared to control (EC50 1.9 μM), and BDNF/TrkB signalling to ~300% of control (EC50 3.2 μM). |
Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|